Global Viral Hemorrhagic Fever Market – Industry Trends and Forecast to 2029

Viral Hemorrhagic Fever Market Analysis and Size

Hemorrhagic fever is rarely a life-threatening disease, but sometimes it leads to emergency medical conditions. The Centers for Disease Control and Prevention (CDC) has witnessed that the natural reservoir (host) for the causative organism of hemorrhagic fever is an animal or insect, but humans are infected when they come into contact with infected hosts. Few examples of viral hemorrhagic fever include ebola, dengue, lassa fever, marburg, and yellow fever. Possible viral hemorrhagic fever-related complications include brain damage, heart failure, kidney damage and malfunctioning of the liver.

Data Bridge Market Research analyses a growth rate in the global viral hemorrhagic fever market in the forecast period 2022-2029. The expected CAGR of global viral hemorrhagic fever market is tend to be around 4.8% in the mentioned forecast period. The market was valued at USD 1.42 billion in 2021, and it would grow upto USD 2.07 billion by 2029. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Viral Hemorrhagic Fever Market Scope and Segmentation

Market Definition

Viral hemorrhagic fever is a form of severe multisystem syndrome that is caused by four families of viruses transmitted by closed contact with infected blood or semen of the patient. The typical sign and symptoms of fever, chills, joint aches, fatigue and weakness. It can be described as an illness caused by four families of RNA viruses: arenaviruses, filoviruses, bunyaviruses and flaviviruses. The overall vascular system in the body gets damaged and the body loses its ability to regulate.

Global Viral Hemorrhagic Fever Market Dynamics

Drivers

• Increased cases of viral hemorrhagic fever

The rising cases of viral hemorrhagic fever among different parts of the country are boosting the growth of the market. In 2021, Ebola virus killed 12 of 23 infected people in Guinea and six of 12 in the DR Congo. There have been numerous cases and outbreaks of Marburg virus disease, with Uganda reporting small outbreaks in 2012 and large outbreaks occurring in central and southern Africa. Thus, it demands advanced treatment and boosts the growth of the market.

• Rise in elderly population

According to research, elderly population is more prone to suffer from this disease. According to the Aging World reports from 2015, there were approximately 562 million people 65 and older worldwide, which increased the disease's incidence and fueled the growth of the hemorrhagic fever treatment market.

Opportunities

• Increasing acquisitions and collaborations

The increasing acquisitions of different market players are creating much opportunities for the market growth. For instance, in August 2016, Teva Pharmaceuticals acquired Allergan’s generics business. This acquisition helped the company deliver the highest-quality generic medicines at the most competitive prices and unlocking value to patients, healthcare systems and investors worldwide.

Restraints/Challenges

• Lack of standard cure

The lack of treatments for viral hemorrhagic fever is hampering the growth of the market. The treatment is costly due to the lack of FDA-approved drugs, leading to lower affordability. No current treatment can cure viral hemorrhagic fevers and immunizations exist for only two of the many viral hemorrhagic fever hindering the market’s growth.

• High generic influx

The patent expiry of most of the drugs has surfaced the way for the entry of generics into the market. The extreme use of generic medicine can hamper the demand for branded drugs, thus affecting the market.

This global viral hemorrhagic fever market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global viral hemorrhagic fever market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development:

• In December 2019, Sarepta Therapeutics Inc., the leader in precision genetic medicine for rare diseases, collaborated with Roche Group to escalate the speed with which SRP-9001 could benefit DMD patients globally.

Global Viral Hemorrhagic Fever Market Scope

The global viral hemorrhagic fever market is segmented on the basis of therapy type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Therapy Type

• Antiviral
• Electrolytes
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Viral Hemorrhagic Fever Market Regional Analysis/Insights

The global viral hemorrhagic fever market is analyzed and market size insights and trends are provided by therapy type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global viral hemorrhagic fever market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is the dominating region due to the increase prevalence of haemophilus influenzae infection and advanced healthcare facilities.

Asia-Pacific is considered the growing region due to the increase’s cases of cardiovascular diseases and rapidly aging population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Global Viral Hemorrhagic Fever Market Share Analysis

The global viral hemorrhagic fever market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global viral hemorrhagic fever market

Key players operating in the global viral hemorrhagic fever market include:

• Novartis AG (Switzerland)
• Endo International Inc (Ireland)
• Teva Pharmaceutical Industries Ltd (Israel)
• Glenmark Pharmaceuticals Ltd (India)
• Cipla Inc (India)
• Dr Reddy's Laboratories Ltd (India)
• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc (U.S.)
• Zydus Group (India)
• Lupin (India)
• Amorphex Therapeutics Holdings, Inc (U.S.)
• Bausch Health Companies Inc. (Canada)

SKU-54544